Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine

New England Journal of Medicine

Volumn 334, Issue 16, 1996, Pages 1011-1017

  Collier, Ann C ^a,k   Coombs, Robert W ^a   Schoenfeld, David A ^b   Bassett, Roland L ^b   Timpone, Joseph ^c   Baruch, Alice ^d   Jones, Michelle ^e   Facey, Karen ^e   Whitacre, Caroline ^f   McAuliffe, Vincent J ^g   Friedman, Harvey M ^h   Merigan, Thomas C ⁱ   Reichman, Richard C ^j   Hooper, Carol ^a   Corey, Lawrence ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d HOFFMANN LA ROCHE INC   (United States)

^e ROCHE PRODUCTS LTD   (United Kingdom)

^f OHIO STATE UNIVERSITY   (United States)

^g NEW YORK UNIVERSITY   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ STANFORD UNIVERSITY   (United States)

^j UNIVERSITY OF ROCHESTER   (United States)

^k NONE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; NEOPTERIN; SAQUINAVIR; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS DETECTION; VIRUS REPLICATION;

ADULT; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; ISOQUINOLINES; MALE; QUINOLINES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SAQUINAVIR; TREATMENT OUTCOME; ZALCITABINE; ZIDOVUDINE;

EID: 2442723342     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199604183341602     Document Type: Article

References (41)

1. Fischl MA, Richman DD, Grieco MH, et al The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med 1987,317: 185-91
2. Fischl MA, Richman DD, Causey DM, et al Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex JAMA 1989, 262:2405-10.
3. Creagh-Kirk T, Doi P, Andrews E, et al. Survival experience among patients with AIDS receiving zidovudine: follow-up of patients in a compassionate plea program. JAMA 1988,260:3009-15.
4. Moore RD, Keruly J, Richman DD, Creagh-Kirk T, Chaisson RE Natural history of advanced HIV disease in patients treated with zidovudine AIDS 1992;6:671-7.
5. Moore RD, Hidalgo J, Sugland BW, Chaisson RE. Zidovudine and the natural history of the acquired immunodeficiency syndrome. N Engl J Med 1991;324:1412-6.
6. Vella S, Giuliano M, Pezzotti P, et al. Survival of zidovudine-treated patients with AIDS compared with that of contemporary untreated patients. JAMA 1992;267:1232-6
7. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy Science 1989,243.1731-4.
8. Larder BA, Kemp SD Multiple mutations in HIV-1 reverse transcriptase confer high level resistance to zidovudine (AZT) Science 1989;246:1155-8.
9. Edlin BR, St Clair MH, Pitha PM, et al. In-vitro resistance to zidovudine and alpha-interferon in HIV-1 isolates from patients, correlations with treatment duration and response. Ann Intern Med 1992;117:457-60. [Erratum, Ann Intern Med 1992;117:879.]
10. Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med 1987;317:192-7
11. Kahn JO, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992;327 581-7
12. Abrams DI, Goldman AI, Launer C, et al. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. N Engl J Med 1994,330.657-62.
13. Spruance SL, Pavia AT, Peterson D, et al. Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine: a randomized, double-blind clinical trial Ann Intern Med 1994;120:360-8.
14. Kramer RA, Schaber MD, Skalka AM, Ganguly K, Wong-Staal F, Reddy EP. HTLV-III gag protein is processed in yeast cells by the virus pol-protease. Science 1986;231 1580-4.
15. Lambert DM, Petteway SR Jr, McDanal CE, et al. Human immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cells. Antimicrob Agents Chemother 1992; 36:982-8.
16. Ashorn P, McQuade TJ, Thaisrivongs S, Tomasselli AG, Tarpley WG, Moss B. An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. Proc Natl Acad Sci U S A 1990;87:7472-6.
17. McQuade TJ, Tomasselli AG, Liu L, et al. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. Science 1990;247:454-6.
18. Craig JC, Duncan IB, Hockley D, Grief C, Roberts NA, Mills JS. Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. Antiviral Res 1991;16.295-305
19. Craig JC, Whittaker LN, Duncan IB, Roberts NA In vitro anti-HIV and cytotoxicological evaluation of the triple combination: AZT and ddC with HIV protease inhibitor saquinavir (Ro 31-8959). Antiviral Chem Chemother 1994, 5:380-6.
20. Craig JC, Duncan IB, Whittaker L, Roberts NA. Antiviral synergy between inhibitors of HIV protease and reverse transcriptase. Antiviral Chem Chemother 1993,4:161-6.
21. Johnson VA, Merrill DP, Chou TC, Hirsch MS. Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2́,3́-dideoxycytidine, or recombinant interferon-α A against zidovudine-sensitive or -resistant HIV-1 in vitro J Infect Dis 1992;166.1143-6.
22. Kitchen VS, Skinner C, Ariyoshi K, et al. Safety and activity of saquinavir in HIV infection. Lancet 1995;345 952-5.
23. Vella S. HIV therapy advances: update on a protease inhibitor. AIDS 1994; 8:Suppl 3:S25-S29.
24. Williams PEO, Muirhead GJ, Madigan MJ, Mitchell AM, Shaw T. Disposition and bioavailability of the HIV-proteinase inhibitor, Ro 31-8959, after single doses in healthy volunteers Br J Clin Pharmacol 1992;34:155P-156P. abstract.
25. Muirhead GJ, Shaw T, Williams PEO, Madigan MJ, Mitchell AM, Houston AC. Pharmacokinetics of the HIV-proteinase inhibitor, Ro 318959, after single and multiple oral doses in health volunteers. Br J Clin Pharmacol 1992; 34:170P-171P. abstract.
26. Guidelines for the performance of CD4+ T-cell determinations in persons with human immunodeficiency virus infection. MMWR Morb Mortal Wkly Rep 1992;41(RR-8):1-17.
27. Hollinger FB, Bremer JW, Myers LE, Gold JWM, McQuay L. Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. J Clin Microbiol 1992;30:1787-94.
28. Fiscus SA, DeGruttola V, Gupta P, et al. Human immunodeficiency virus type 1 quantitative cell microculture as a measure of antiviral efficacy in a multicenter clinical trial. J Infect Dis 1995;171 305-11
29. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol 1994;32:292-300.
30. Lin HJ, Myers LE, Yen-Lieberman B, et al. Multicenter evaluation of quantification methods for plasma human immunodeficiency virus type 1 RNA. J Infect Dis 1994;170:553-62.
31. Pachl C, Todd JA, Kern DG, et al. Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay. J Acquir Immune Defic Syndr Hum Retroviral 1995,8:446-54.
32. Cao Y, Ho DD, Todd J, et al. Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma. AIDS Res Hum Retroviruses 1995;11:353-61.
33. Todd J, Yeghiazarian T, Hoo B, et al. Quantitation of human immunodeficiency virus plasma RNA by branched DNA and reverse transcription coupled polymerase chain reaction assay methods: a critical evaluation of accuracy and reproducibility. Serodiagn Immunother Infect Dis 1994;6:233-9.
34. Dewar RL, Highbarger HC, Sarmiento MD, et al. Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma. J Infect Dis 1994;170:1172-9.
35. Schoenfeld DA, Finkelstein DM, Richman DD. Designing phase II studies of chemotherapy for HIV infection using CD4 as an endpoint. AIDS 1993; 7 955-8
36. The Lifereg procedure. In: SAS/STAT user's guide, version 6 4th ed. Vol. 2. Cary N.C.: SAS Institute, 1989:997-1025.
37. Mehta CR, Patel NR, Tsiatis AA. Exact significance testing to establish treatment equivalence with ordered categorical data. Biometrics 1984;40:819-25.
38. Hooper C, Welles S, D'Aquila R, et al. HIV-1 RNA level in plasma and association with disease progression, zidovudine sensitivity phenotype and genotype, syncytium-inducing phenotype, CD4+ cell count and clinical diagnosis of AIDS. In: Proceedings of the Third International HIV Drug Resistance Workshop, Kauai, Hawaii, Aug. 2-5, 1994. abstract.
39. O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996;334:426-31.
40. Yerly S, Kaiser L, Mermillod B, Baumberger C, Hirschel B, Perrin L. Response of HIV RNA to didanosine as a predictive marker of survival. AIDS 1995;9:159-63.
41. Fischl MA, Stanley K, Collier AC, et al. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann Intern Med 1995,122:24-32.